 Parsippany, NJ, Feb. 01, 2021 GLOBE NEWSWIRE -- Interpace Biosciences, Inc. Nasdaq: IDXG announced today that it has executed a license agreement with Rutgers, The State University of New Jersey, and Massachusetts General Hospital for a novel monoclonal antibody platform, Das-1, used in the risk assessment of pancreatic cysts. Although some cysts may have no cancerous potential at all, other cysts carry up to a 48 percent chance of harboring invasive cancer, and surgery to remove them is often complex. Therefore, there is a need to develop additional tools to identify which pancreatic cysts may develop into cancer and which ones will not. In a recent, national multicenter study of patients undergoing surgery for pancreatic cysts, the Das-1 antibody was able to accurately identify pancreatic cysts likely to become cancerous with high sensitivity and high specificity in comparison to current clinical guidelines Das, K et al, Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesion, Gastroenterology 2019; 157:720-730. Das-1 is gaining recognition among experts in the GI community as evidenced by its inclusion as a component in the Pancreatic Cyst Biomarker Alliance sponsored in part by the National Cancer Institute. 